Olav Hellebø, a seasoned biotech executive, has been appointed chief executive officer of BerGenBio ASA, a Norwegian company developing AXL kinase inhibitors for cancer. Since 2023 he has served as board director at the immuno-oncology company Cytovation ASA whilst also acting as a consultant to industry on strategies for building pipelines and commercialising drugs across multiple therapeutic areas. Before this, he was CEO at ReNeuron Group Plc, a UK-based cell therapy company. Mr Hellebø holds a Master of Business Administration from the IESE Business School.
BerGenBio announced the appointment on 20 November 2024
Copyright 2024 Evernow Publishing Ltd